{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T14:40:08Z","timestamp":1784385608469,"version":"3.55.0"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.5712","type":"journal-article","created":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T22:05:45Z","timestamp":1457993145000},"page":"623-627","source":"Crossref","is-referenced-by-count":9,"title":["Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature"],"prefix":"10.2169","volume":"55","author":[{"given":"Jen-Wei","family":"Chou","sequence":"first","affiliation":[{"name":"School of Medicine, China Medical University, Taiwan"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, China Medical University Hospital, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Sheng","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Medicine, China Medical University, Taiwan"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, China Medical University Hospital, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Education, China Medical University Hospital, Taiwan"},{"name":"School of Chinese Medicine, China Medical University, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Abramson RG, Abramson VG, Chan E, et al. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol 200: 475-483, 2013.","DOI":"10.2214\/AJR.12.9049"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965-972, 2005.","DOI":"10.1200\/JCO.2005.06.124"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37: 755-762, 2007.","DOI":"10.1093\/jjco\/hym095"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Minami H, Kawada K, Ebi H, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99: 1492-1498, 2008.","DOI":"10.1111\/j.1349-7006.2008.00837.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505-2512, 2006.","DOI":"10.1200\/JCO.2005.03.6723"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004.","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12: 7271-7278, 2006.","DOI":"10.1158\/1078-0432.CCR-06-1249"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lammert E, Cleaver O, Melton D. Induction of pancreatic differentiation by signals from blood vessels. Science 294: 564-567, 2001.","DOI":"10.1126\/science.1064344"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Loriot Y, Perlemuter G, Malka D, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 5: 268-278, 2008.","DOI":"10.1038\/ncponc1087"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Peron J, Khenifer S, Potier V, et al. Axitinib-induced acute pancreatitis: a case report. Anti-Cancer Drugs 25: 478-479, 2014.","DOI":"10.1097\/CAD.0000000000000076"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wang HE, Chen CT, Huang HH. Sorafenib-induced acute pancreatitis. J Med Sci 34: 126-128, 2014.","DOI":"10.4103\/1011-4564.134392"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Amar S, Wu KJ, Tan WW. Sorafenib-induced pancreatitis. Mayo Clin Proc 2007 82: 516-522, 2007.","DOI":"10.4065\/82.4.521"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J 100: 909-911, 2007.","DOI":"10.1097\/SMJ.0b013e31813c695d"},{"key":"14","unstructured":"14. Saadati H, Saif MW. Sorafenib-induced acute pancreatitis. J Pancreas 11: 283-284, 2010."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kobayashi Y, Kanemitu T, Kamoto A, et al. Painless acute pancreatitis associated with sorafenib treatment: a case report. Med Oncol 28: 463-465, 2011.","DOI":"10.1007\/s12032-010-9479-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sevin A, Chen A, Atkinson B. Tyrosine kinase inhibitor induced pancreatitis. J Oncol Pharm Pract 19: 257-260, 2103.","DOI":"10.1177\/1078155212457968"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fukudo M, Ito T, Mizuno T, et al. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. Clin Pharmacokinet 53: 185-196, 2014.","DOI":"10.1007\/s40262-013-0108-z"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35: 692-706, 2009.","DOI":"10.1016\/j.ctrv.2009.08.004"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Jain L, Woo S, Gardner ER, et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 72: 294-305, 2011.","DOI":"10.1111\/j.1365-2125.2011.03963.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Boudou-Rouquette P, Narjoz C, Golmard JL, et al. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One 7: e42875, 2012.","DOI":"10.1371\/journal.pone.0042875"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical parmacokinetics. Cancer Chemother Pharmacol 57: 685-692, 2006.","DOI":"10.1007\/s00280-005-0068-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50: 551-603, 2011.","DOI":"10.2165\/11593320-000000000-00000"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Zimmerman EI, Roberts JL, Li L, et al. Ontogeny and sorafenib metabolism. Clin Cancer Res 18: 5788-5795, 2012.","DOI":"10.1158\/1078-0432.CCR-12-1967"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92: 414-417, 2012.","DOI":"10.1038\/clpt.2012.96"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Peer CJ, Sissung TM, Kim A, et al. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res 18: 2099-2107, 2012.","DOI":"10.1158\/1078-0432.CCR-11-2484"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12: 426-437, 2007.","DOI":"10.1634\/theoncologist.12-4-426"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Mathijssen RH, Sparreboom A. Influence of lean body weight on anticancer drug clearance. Clin Pharmacol Ther 85: 23, 2009.","DOI":"10.1038\/sj.clpt.6100511"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Hornecker M, Blanchet B, Billemont B, et al. Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest New Drugs 30: 1991-2000, 2012.","DOI":"10.1007\/s10637-011-9760-z"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/6\/55_55.5712\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T08:18:41Z","timestamp":1498292321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/6\/55_55.5712\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.5712","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}